Objective: This study aimed to investigate the efficacy and safety of sofosbuvir plus ribavirin for the treatment of hepatitis C virus (HCV) genotype 2 infection and to determine the optimal ribavirin dosage. Results: A sustained virological response was achieved in 189 patients (intention-to-treat [ITT] 97.4%; per protocol [PP]: 99.5%, both at 12 and 24 weeks) whose average ribavirin dosage was 937.1 mg/day. The most frequent adverse event was anemia (17.5%), and its incidence significantly increased (P < 0.001) with a higher ribavirin dosage per body weight. Discontinuation of ribavirin or dosage reduction occurred in 27 (14.2%). The ribavirin dosage reduction rate increased at a dosage of >15 mg/kg (area under the receiver operating characteristic curve 0.652, 95% confidence interval [CI] 0.54-0.76, P = 0.01). Multivariate analysis showed that age ≥70 years, with liver cirrhosis, and female gender were associated with ribavirin dosage reduction.
| INTRODUCTION
Hepatitis C virus (HCV) infection results in hepatitis, liver cirrhosis, and even hepatocellular carcinoma (HCC). The management of HCV infection is challenging because of a limited number of treatment options. [1] [2] [3] The only treatment option shown to reduce patient's mortality was pegylated interferon (peginterferon) plus ribavirin. 4 However, treatment for HCV infection has now entered a new era, owing to the introduction of direct-acting antivirals. 5 Currently, various direct-acting antivirals have been introduced and used to treat infections caused by various HCV genotypes. For HCV genotype 2, current guidelines recommend several key treatment regimens, including glecaprevir plus pibrentasvir, sofosbuvir plus Jae Hyun Yoon and Chung Hwan Jun contributed equally to this work as first authors.
velpatasvir, and sofosbuvir plus ribavirin. [6] [7] [8] According to the Korean Association for the Study of the Liver (KASL) guidelines, 9 the standard therapy for HCV genotype 2 infection is sofosbuvir (400 mg/day) plus ribavirin (1 200 mg/day in patients with a body weight ≥75 kg, and 1 000 mg/day for those weighted <75 kg) for 12 to 16 weeks, and this regimen has been used in Korea since 2016. The treatment regimen of glecaprevir plus pibrentasvir has been added to the recently updated 2017 KASL guidelines, which have not been released in Korea yet. 10 Several studies on the use of sofosbuvir plus ribavirin for treating HCV genotype 2 infection have revealed substantial variations in sustained virological response (SVR) among distinct groups of patients, and the appropriate dosage of ribavirin for HCV treatment remains controversial because of its efficacy and safety issues. [11] [12] [13] [14] [15] [16] [17] In the era of peginterferon plus ribavirin, despite a high likelihood of ribavirin dosage reduction, the ribavirin dosage starts from 1 200 mg/day or 1 000 mg/day because of a poor treatment response. 18 An increasing probability of anemia at a higher ribavirin dosage per body weight has been reported; considering the comparably lower weight in Asian populations, a fixed dose of 1 000 mg/day seems inadequate to apply in clinical practice for patients <75 kg (which applies to most of the patients). 19 HCV prevalence in Korea varies by regions. HCV genotype 2 is the second most common genotype in Korea, accounting for 45.3% of all cases. 20 Owing to its aging population, a higher prevalence of advanced diseases, such as liver cirrhosis, and geographical characteristics, Jeollanam-do Province has the highest HCV infection rate in Korea. 21, 22 However, to our knowledge, no studies have investigated HCV treatment outcomes in this province.
Therefore, in this study, we assessed the efficacy and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection in patients from Jeollanam-do Province in real-world settings in order to determine the appropriate ribavirin dosage.
| PATIENTS AND METHODS

| Patients
The inclusion criteria of the patients were adult patients (age and (c) those who discontinued the medication.
This study was approved by the Institutional Review Board of all the participating hospitals, and written informed consent requirement was waived because the patients' data were de-identified. 
| Clinical and laboratory assessments
| Treatment of HCV genotype 2 infection
All enrolled patients were treated with sofosbuvir and ribavirin. The dosage of sofosbuvir (Sovaldi; Gilead Sciences, Seoul, Korea) was fixed at 400 mg/day, and that of ribavirin (Viramid; Ilsung Pharmaceuticals, Seoul, Korea) was determined by the physicians on the basis of the patient's baseline weight, hemoglobin level, underlying comorbidities, and the occurrence of diverse medication-related complications during the treatment. Because the ribavirin dosage was changed for some patients during treatment, the average ribavirin dosage was calculated for the entire treatment period. Patients with and without liver cirrhosis were treated for 16 and 12 weeks, respectively.
| Measurement of HCV RNA and assessment of treatment efficacy
HCV RNA was measured using a real-time PCR assay, and the lower limit of HCV RNA quantification was 15 IU/mL at all centers. The criteria for viral breakthrough were an increase in HCV RNA >1 log 10 from the nadir or to a level greater than the lower limit of quantification, if HCV RNA was previously undetectable. While the criterion for the positive end-of-treatment response was undetectable HCV RNA after 12 to 16 weeks of treatment. SVR was defined as undetectable HCV RNA at 12 or 24 weeks after treatment, according to the KASL guidelines.
| Dosage of ribavirin
Data for every ribavirin dosage that was prescribed to a patient were collected and assessed. The mean ribavirin dosage was defined as the average ribavirin dosage during the entire treatment period, reflecting intermittent decrements due to adverse events. In addition, the ribavirin dosage was divided by patients' weight to analyze the actual dosage of the medication, which was normalized to each patient's weight.
| Statistical analysis
All the statistical analyses were conducted using the SPSS for Win- 
| RESULTS
Information on study enrollment and treatment efficacy is presented in Figure 1 . We enrolled 199 patients who were treated with sofosbuvir plus ribavirin for HCV genotype 2 infection between May 2016
and March 2017. Among these patients, five were excluded because they had insufficient data (n = 1) or were lost to follow-up (n = 4).
Thus, data of 194 patients were included in the final retrospective analysis. Among the 194 patients, four patients discontinued medication because of adverse events (n = 3) or an economic burden (n = 1).
The baseline characteristics of the study patients are presented in Table 1 .
| Treatment outcomes in patients treated with sofosbuvir plus ribavirin
After the initiation of antiviral treatment the negative conversion rate of HCV RNA was recorded and calculated. Among the 194 patients, 183 (94.3%) had undetectable HCV RNA levels 4 weeks after the initiation of treatment. And at 8 weeks, 190 (97.9%) patients achieved an HCV RNA-negative status, which persisted throughout the entire treatment period ( Table 2 ). The four patients who discontinued medication after 4 weeks of treatment were included in this analysis. SVR was achieved in all the remaining seven patients who had detectable HCV RNA at the 4-week examination. discontinued medication because of nausea/vomiting or the cost of the medication, and only one patient had a viral relapse at 12 weeks after the end of therapy (Table 2 ). This 62-year-old woman had no prior history of antiviral therapy. Her HCV genotype was 2a/c, and the baseline RNA level was 2.37 × 10 6 IU/mL. She received medication for 12 weeks, and HCV RNA was undetectable at 4 weeks after the initiation of the therapy. However, a blood test performed at 12 weeks after the end of treatment showed that her viral load had increased to 5.75 × 10 6 IU/mL.
| Adverse events
Anemia was the most common adverse event (17.5%), with fatigue being the second most common (11.3%). The various adverse events and their incidence rates are presented in Table 3 . Four patients could not complete the 12-to 16-week medication regimen, among them three stopped treatment because of severe nausea, vomiting, and fatigue.
| Ribavirin dosage reduction and the development of anemia
Data on ribavirin dosage reduction were analyzed in patients who completed the whole treatment (n = 190). All patients received ribavirin; however, discontinuation of ribavirin or a dosage reduction became necessary in 27 (14.2%) patients. Among these patients, the ribavirin dosage was reduced in 22 (11.6%) because of anemia, in two (1.1%) patients each because of weakness and dizziness, respectively, and in one (0.5%) patient because of severe pruritus.
We compared the initial and mean ribavirin dosages between the two groups, the patients with and without ribavirin dosage reduction (Table 4) . When the initial ribavirin dosage was normalized to the patient's weight, the value was markedly higher in the group with ribavirin dosage reduction than in the group without (17.1 mg/kg vs. Of the 34 (17.9%) patients who developed anemia during the treatment, 22 (11.6%) of whom required a decrease in the ribavirin dosage. There were no significant differences in the initial ribavirin dosage per day or the mean ribavirin dosage normalized to the body weight between patients with and without anemia. However, the initial normalized ribavirin dosage was significantly higher in patients who developed anemia than in those who did not (17.5 mg/kg vs.
15.5 mg/kg, P < 0.001). In addition, the mean ribavirin dosage per day was lower in the patients who developed anemia than in those who did not (830 mg/day vs. 960 mg/day, P < 0.001) because of the marked ribavirin dosage reduction during the treatment period in the former group.
We then performed univariate and multivariate analyses to evaluate whether factors other than the ribavirin dosage influenced the likelihood of ribavirin dosage reduction ( Table 5 ). The multivariate analysis with logistic regression revealed that the following factors were significantly related to ribavirin dosage reduction, in decreasing order of correlation strength: female gender, the presence of liver cirrhosis, and an advanced age (≥70 years). Abnormal liver function test (LFT) was defined as an elevation of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) to a level of more than thrice the upper limit of normal.
| DISCUSSION
This is the first multicenter study providing data on the real-world efficacy and safety of the treatment with sofosbuvir plus ribavirin for HCV genotype 2-infected patients in Jeollanam-do province, Korea.
Moreover, to our knowledge, this is the first study to assess the risk factors for ribavirin dosage reduction and to suggest an optimal ribavirin dosage for HCV infection, which is individualized according to the patients' body weight.
Although previous studies have reported lower SVR rates in patients with liver cirrhosis, different subtypes of genotype 2, a high baseline viral load, and prior treatment failure, 11,13-15 we found no factors that were significantly related to the SVR rate in our study, probably because of the small sample size of those who failed to achieve SVR. A prior history of HCV treatment is regarded as a risk factor for treatment failure. The proportion of patients with a history of prior HCV treatments was lower in the current study (13.4%) than in previous real-world studies (28%-34.2%), 14, 16, 17 which may explain the high SVR rate in this study. Some studies have reported low SVR rates in patients with cirrhosis who received 12 weeks of treatment. 16 However, our study and other studies with a treatment period of ≥16 weeks in patients with cirrhosis, including a study 11 of sofosbuvir plus ribavirin in patients infected with HCV genotype 2, reported SVR rates of >90%. 16, 23 Tacke et al. 16 have reported that being aged >70 years is a predictor of poor SVR prognosis (73%, P = 0.26); however, the mean age of patients in the present study (61.2 years) was considerably younger than 70 years. The HCV-TARGET study, in which the median patient age was 59.0 years, reported an SVR rate of 92.3%, 17 and studies con- A U.S. study of veterans, in which men comprised 96.6% of the participants infected with HCV genotype 2 who were treated with sofosbuvir plus ribavirin, reported a low SVR rate of 79.0%. 25 This suggests that the high proportion of female patients in the present study (52.0%) might have had a positive effect on the SVR rate. Mah et al. 25 have reported that female patients with chronic HCV infection have a higher frequency of the favorable IL28B TT genotype and a lower probability of advanced fibrosis than male patients (odds ratio
[OR] 0.46, 95% CI 0.24-0.91, P = 0.024). Mean ribavirin dosage during the entire treatment period. b Anemia was defined as a hemoglobin level of <100 g/L.
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FIGURE 2 Area under the receiver operating characteristic curve of ribavirin dosage reduction and the ribavirin dosage normalized to the patients' weight In our study, 52 (26.8%) patients had cirrhosis, among whom nine (17.3%) had a MELD score of 10 or higher, which can be regarded as decompensated liver cirrhosis. 27 All nine patients successfully attained SVR and had no viral relapse after the end of treatment.
In addition to low SVR rates, many side effects have been reported in patients receiving ribavirin for the treatment of chronic hepatitis C. 28, 29 In the present study, although no life-threatening events such as hepatic failure or hypovolemic shock due to severe anemia were observed, many mild adverse events occurred during the treatment, and three patients could not complete the treatment regimen because of severe fatigue, nausea, and vomiting. The most common adverse event was anemia, which is a well-known side effect of ribavirin. Among the 190 patients, 27 (14.2%) required a reduction of ribavirin dosage or drug discontinuation because of adverse events, including 22 (11.6%) patients who developed anemia during the treatment. Our data showed that a high initial ribavirin dosage (normalized to the body weight) was related to higher possibilities of both ribavirin dosage reduction and the development of anemia. These findings suggest that clinicians should carefully choose the ribavirin dosage, taking into consideration each patient's body weight and the risk of developing adverse effects, especially anemia.
The KASL guidelines recommend a ribavirin dosage of 1200 mg/day for patients ≥75 kg and 1000 mg/day for those <75 kg. 9 The mean initial ribavirin dosage in our enrolled patients was 970.5 mg/day, which was lower than the currently recommended dosage. Most Korean patients do not weigh more than 75 kg, and the mean body weight of the enrolled patients in our study was 61.9 kg.
In addition, because Asian patients show a greater tendency to develop anemia, the clinicians used an initial ribavirin dosage of <1000 mg/day to mitigate the risk of anemia. These factors had probably influenced the clinicians' decisions, resulted in a low mean initial ribavirin dose of <1000 mg/day. The remarkably high SVR rate (ITT analysis: 97.4%; PP analysis: 99.5%) achieved in the present study, with the mean ribavirin dosage of 937.1 mg/day, suggests that the currently recommended ribavirin dosage of ≥1000 mg/day for HCV genotype 2 infection may be unnecessarily high. In addition, the occurrence of adverse events and the possibility of serious complications that may result in the discontinuation of ribavirin therapy also support a ribavirin dosage of <1000 mg/day. Our data show that the ribavirin dosage and the dosage reduction rate are closely correlated to the patients' body weight. Patients treated with a mean ribavirin dosage of ≤15 mg/kg had a lower likelihood of ribavirin dosage reduction, with no effect on SVR. Therefore, we suggest that 15 mg/kg is the optimal ribavirin dosage for treating HCV genotype 2 infection.
In addition, various other factors, such as liver cirrhosis, female gender, and an advanced age (≥70 years), which have not been previously investigated, were correlated with the likelihood of ribavirin dosage reduction in our study. Patients aged 70 years or elder and those with cirrhosis were more likely to have the ribavirin dosage reduced. Female gender had the highest association with the incidence of ribavirin dosage reduction. Therefore, to achieve a successful SVR, clinicians should consider patient-related factors when selecting the ribavirin dosage.
This study had some limitations. First of all, the study was based on retrospective data, and several patients were lost to follow-up and had insufficient data for analysis. However, considering that SVR is strongly correlated with the eradication rate of HCV, the high SVR rate achieved in the present study suggests that sofosbuvir plus ribavirin can provide excellent treatment outcomes. 30 Second, because most of the enrolled patients were residents of Jeollanam-do Province, caution should be exercised when applying these findings to all patients infected with HCV genotype 2 infection in Korea and worldwide. Further studies of treatment outcomes in patients with HCV genotype 2 infection from other provinces and long-term results of viral quantification are needed.
In conclusion, this study shows that sofosbuvir plus ribavirin has a remarkable efficacy against HCV genotype 2 infection in Korea. We 
